Prof John G Gribben Consultant Profile
Professor John Gribben graduated from the University of Glasgow in 1980. He subsequently trained in Haematology at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, where he remained on the faculty for 17 years before returning to the UK.
He specialises in haematological cancers including lymphomas, leukaemias, myeloma, bone marrow transplantation and CAR-T therapy.
His primary post is as Professor of Medical Oncology at Barts Cancer Institute, Queen Mary University of London and he has an Honorary Contract in the NHS as Consultant in Haemato-Oncology and Medical Oncologist at Barts Health NHS Trust, He serves as the Director of the stem Cell Transplant Program and CAR-T program at Barts.
He is the author of more than 600 articles and chapters in peer-reviewed publications and has a global reputation for his work in researching new drugs and forms of cancer treatment. He has held numerous grant funding from The National Cancer Institute and Cancer Research UK for pioneering studies in leukaemia and lymphoma.
He was an elected as a member of the American Society for Clinical Investigation and a Fellow of the Academy of Medical Science of the Academy of Medical Science. He served as President of the European Heamatology Association and as an Editor of the journal Blood. He was a founding member of the CLL Research Consortium and was awarded the Binet-Rai medal for CLL research from iwCLL in 2017. He is Chair of the international workshop on non-Hodgkin’s Lymphoma (iwNHL) and served as chair of the international workshop for CAR-T cells (iwCART). He was awarded the prestigious Jose Carreras Career Development Medal acknowledging his lifetime contributions to research in haematologic malaignancies in 2024.
He has sat on and chaired numerous international executive committees dedicated to investigating new approaches to cancer care, and several of the editorial boards for professional publications which are focused on cancer. He has lectured across the world on new therapies for cancer treatment.
Areas of expertise
- Management of all aspects of treatment of non-Hodgkin and Hodgkin lymphoma from diagnosis thorugh first line and salvage therapies including stem cell transplant
